GMP Semaglutide Powder Pharma Grade 99%

Semaglutide exerts its effects as a GLP-1 receptor agonist. After binding to GLP-1 receptors on the membrane of pancreatic β cells, it increases intracellular cAMP levels, which leads to the opening of calcium channels, elevation of intracellular Ca²⁺ concentrations, and-on the basis of glucose entering the cell through GLUT2, increased ATP production, and closure of KATP channels-further enhances insulin secretion to improve glycemic control. At the same time, semaglutide suppresses glucagon secretion from pancreatic α cells, thereby reducing hepatic glucose output, and it modulates gastrointestinal function by delaying gastric emptying, which lowers postprandial glucose peaks. In addition, it acts on appetite-regulating centers in the central nervous system to induce satiety and decrease appetite, reducing energy intake and promoting weight loss. Overall, the drug improves both blood glucose and body weight through multiple mechanisms, including stimulation of insulin secretion, inhibition of glucagon release, delayed gastric emptying, and appetite suppression.